Breast Cancer
Conditions
Keywords
bone health, hormone-sensitive breast cancer, postmenopausal, aromatase inhibitor, bone mineral density
Brief summary
This multicenter, randomized, comparative study will evaluate the efficacy of denosumab to prevent the adjuvant therapy of aromatase inhibitors-induced loss of bone mineral density (BMD) in breast cancer patients with normal BMD. Investigators will compare the inhibitory effects of denosumab on bone loss between participants with normal BMD to whom Letrozole or Arimidex will be administered as postoperative endocrine therapy for stage I-IIIA postmenopausal hormone-sensitive breast cancer and controls.
Detailed description
Normal BMD means T score is ≥-1.0 for the lumbar vertebrae (L1-L4) and/or the femoral neck.
Interventions
AI intake + denosumab injection per 6 months VS only AI intake
Sponsors
Kyoto Prefectural University of Medicine
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
PREVENTION
Masking
NONE
Eligibility
Sex/Gender
FEMALE
Age
20 Years to No maximum
Healthy volunteers
No
Inclusion criteria
Patients must meet all of the following items at the time of case registration: 1. Patients with infiltrative breast cancer, aged ≥20 years, meeting the following definitions: * Those pathologically diagnosed with stage I, II, or IIIA breast cancer (Cancer Management Regulations, 11th version) * Those who underwent appropriate surgery, such as mastectomy and breast-preserving surgery 2. Estrogen receptor (ER)- or progesterone receptor (PgR)-positive patients on immunohistochemical (IHC) staining 3. Females meeting one of the following criteria for menopause: * Those, aged ≥55 years, without menstruation * Those, aged \<55 years, with amenorrhea for ≥12 months, or those diagnosed with menopause by attending physicians based on the FSH and estradiol levels * Those who underwent bilateral oophorectomy 4. Patients in whom the BMD for the lumbar vertebrae (L1-L4) on DXA before the start of this study is ≥-1.0SD of the mean value of young adult females (YAM), and the BMD for the femoral neck is ≥-1.0SD of YAM 5. Patients without lumbar vertebral or femoral fracture 6. Those with an ECOG PS of 0-2 7. Those with adequate organ functions (laboratory data within 4 weeks before case registration) * Leukocyte count, ≥3,000/mm3 or Neutrophil count, ≥1,500/mm3 * AST, ALT, ≤1.5-fold of the upper limit of the institutional reference range * Serum creatinine, ≤1.5-fold of the upper limit of the institutional reference range 8. Case registration should be performed before the following point:Twelve weeks after the completion of surgery or postoperative chemotherapy (The completion of chemotherapy refers to the completion of the final course, involving the recovery phase.) 9. Patients with an interval of ≥4 weeks after the discontinuation of therapy with bisphosphonates (oral preparations), estrogen preparations, raloxifene, calcitonin preparations, vitamin K preparations, active vitamin D preparations, or ipriflavone preparations, which influence bones 10. Those from whom written informed consent regarding study participation was obtained
Exclusion criteria
Whether each patient meets any of the following items must be checked on case registration: 1. Patients in whom distant metastasis was confirmed clinically or using imaging procedures at the time of case registration 2. Those with bilateral breast cancer 3. Those for whom postoperative hormonal therapy was started before consenting to study participation 4. Those who received endocrine therapy within 52 weeks before consenting to study participation 5. Those to whom bisphosphonate preparations were intravenously administered within 52 weeks before consenting to study participation 6. Those with the following diseases that may affect DXA * Severe scoliosis, immobility, hyperostosis or osteosclerosis of the lumbar vertebrae, calcification of the abdominal aorta, and vertebral disease 7. Those with a history of malignant tumors other than breast cancer within 260 weeks before consenting to study participation 8. Those with dental diseases, such as infectious diseases of the teeth or jaw and tooth trauma. Those for whom tooth or jaw surgery is scheduled within 6 weeks after consenting to study participation (tooth extraction, implantation) 9. Others who are considered to be ineligible by the chief investigator
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| percentage change in the bone mineral density (BMD) for the lumbar vertebrae (L1-L4) on dual-energy X-ray absorptiometry (DXA) | 12 months after the start of this study | The change is a value obtained by subtracting 1 from the BMD after 12 months/baseline BMD is expressed as a percentage |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| percentage change in the BMD for the femoral neck | after 12 months and 2/3/4/5 years | percentage change in the BMD for the femoral neck: After 12 months and 2/3/4/5 years |
| percentage change in the BMD for the radius (an ultrasonic bone densimeter is used)institutions in which ultrasonic bone densimeters are used) | after 2 and 4 weeks, every 4 weeks thereafter (for 2 years after registration)(only | percentage change in the BMD for the radius (an ultrasonic bone densimeter is used): After 2 and 4 weeks, every 4 weeks thereafter (for 2 years after registration)(only institutions in which ultrasonic bone densimeters are used) |
| Changes in Ca and bone metabolism markers | after 24 weeks | Changes in Ca (mg/dL corrected by albumin level) and bone metabolism markers such as TRAP5b, bone-specific alkaline phosphatase (BSAP), blood pentosidine) by blood sampling at every 6 months |
| Appearance rate of morbid fracture in all participants | up to 3 years | Appearance rate of morbid fracture up to 3 years in all participants. Morbid fractures include all types of fractures. |
| percentage change in the BMD for the lumbar vertebrae (L1-L4) on DXA | after 2, 3, 4, and 5 years | percentage change in the BMD for the femoral neck: After 2/3/4/5 years |
| Overall survival | at least 5 year | Overall survival at the end of the study |
| Appearance of adverse events | at least 5 year | Appearance rate of adverse events (such as hypocalcemia and necrosis of the jaw) |
| Quality of life (QOL) | after 24 weeks | Quality of life(QOL), Japanese version Euro-Qol (EQ-5D-5L) evaluated by questionnaire at every 6 months |
| Disease-free survival | at least 5 year | Disease-free survival at the end of the study |
Countries
Japan
Outcome results
None listed